Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 733-741

  Tavolaro, Simona ^a   Chiaretti, Sabina ^a   Messina, Monica ^a   Peragine, Nadia ^a   Del Giudice, Ilaria ^a   Marinelli, Marilisa ^a   Santangelo, Simona ^a   Mauro, Francesca Romana ^a   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic lymphocytic leukemia (CLL); Gene expression profile; IGHV mutational status; MTT assay; PK inhibitors; Protein kinases (PKs)

Indexed keywords

CD38 ANTIGEN; DASATINIB; PROTEIN KINASE; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; TUMOR CELLS, CULTURED; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77952097046     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.11.005     Document Type: Article

References (36)

1. Calligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999, 17:399-408.
2. Maloum K., Davi F., Merle-Beral H., et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000, 96:377-379.
3. Guarini A., Gaidano G., Mauro F.R., et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003, 102:1035-1041.
4. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
5. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
6. Donher H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
7. Cordone I., Masi S., Mauro F.R., et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998, 91:4342-4349.
8. Gentile M., Mauro F.R., Calabrese E., et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005, 130:549-557.
9. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 2000, 19:5636-5642.
10. Kuppers R., Zhao M., Rajewsky K., Hansmann M.L. Detection of clonal B cell populations in paraffin-embedded tissues by polymerase chain reaction. Am J Pathos 1993, 143:230-239.
11. Kuppers R., Zhao M., Hansmann M.L., Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993, 12:4955-4967.
12. Fais F., Ghiotto F., Hashimoto S., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102:1515-1525.
13. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36.
14. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
15. Chen L., Widhopf G., Huynh L., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
16. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
17. Wechsler R.J., Monroe J.G. Src-family tyrosine kinase p55fgr is expressed in murine splenic B cells and is activated in response to antigen receptor cross-linking. J Immunol 1995, 154:3234-3244.
18. Hata A., Sabe H., Kurosaki T., Takata M., Hanafusa H. Functional analysis of Csk in signal transduction through the B-cell antigen receptor. Mol Cell Biol 1994, 14:7306-7313.
19. Dal Porto J.M., Burke K., Cambier J.C. Regulation of BCR signal transduction in B-1 cells requires the expression of the Src family kinase Lck. Immunity 2004, 21:443-453.
20. Dymecki S.M., Niederhuber J.E., Desiderio S.V. Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells. Science 1990, 247:332-336.
21. 2+ mobilization through distinct pathways. EMBO J 1994, 13:1341-1349.
22. Contri A., Brunati A.M., Trentin L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005, 115:369-378.
23. Alkan S., Huang Q., Ergin M., et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005, 79:97-106.
24. Aloyz R., Grzywacz K., Xu Z.Y., Loignon M., Alaoui-Jamali M.A., Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004, 18:409-414.
25. Chow K.U., Nowak D., Hofmann W., Schneider B., Hofmann W.K. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia 2005, 19:1103-1105.
26. Lin K., Glenn M.A., Harris R.J., et al. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res 2006, 66:7801-7809.
27. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
28. Foà R, Vitale A, Guarini A, et al. First line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study. ASH, San Francisco, CA December 6-8, 2008, abs#305.
29. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
30. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
31. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
32. Johnson F.M., Saigal B., Talpaz M., Donato N.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005, 11:6924-6932.
33. Nam S., Kim D., Cheng J.Q., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
34. Amrein L., Hernandez T.A., Ferrario C., et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008, 143:698-706.
35. Veldurthy A., Patz M., Hagist S., et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008, 112:1443-1452.
36. Hallaert D.Y., Jaspers A., van Noesel C.J., van Oers M.H., Kater A.P., Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008, 112:5141-5149.